ClinVar Miner

Submissions for variant NM_001366385.1(CARD14):c.1396G>A (p.Glu466Lys)

gnomAD frequency: 0.00005  dbSNP: rs140734867
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV001347705 SCV001541978 uncertain significance Pityriasis rubra pilaris; Psoriasis 2 2023-11-06 criteria provided, single submitter clinical testing This sequence change replaces glutamic acid, which is acidic and polar, with lysine, which is basic and polar, at codon 466 of the CARD14 protein (p.Glu466Lys). This variant is present in population databases (rs140734867, gnomAD 0.004%). This variant has not been reported in the literature in individuals affected with CARD14-related conditions. ClinVar contains an entry for this variant (Variation ID: 1043577). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt CARD14 protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Mayo Clinic Laboratories, Mayo Clinic RCV003481086 SCV004224447 uncertain significance not provided 2022-12-16 criteria provided, single submitter clinical testing BP4
Ambry Genetics RCV004036528 SCV004920224 uncertain significance Inborn genetic diseases 2024-03-01 criteria provided, single submitter clinical testing The c.1396G>A (p.E466K) alteration is located in exon 10 (coding exon 9) of the CARD14 gene. This alteration results from a G to A substitution at nucleotide position 1396, causing the glutamic acid (E) at amino acid position 466 to be replaced by a lysine (K). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear.
PreventionGenetics, part of Exact Sciences RCV003898331 SCV004717628 uncertain significance CARD14-related disorder 2024-02-01 no assertion criteria provided clinical testing The CARD14 c.1396G>A variant is predicted to result in the amino acid substitution p.Glu466Lys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.0040% of alleles in individuals of African descent in gnomAD. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.